Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MenACWY liquid

PreclinicalBiologic

MenACWY liquid is one of 29 biologic programs targeting Gonorrhea. It is currently in Preclinical.

3

Indications

8

Total Trials

0

Active Trials

28

Competitors

Pipeline

Status by Indication[3][1]

Indication

GonorrheaActive, not recruiting

Vaccine ResponseCompleted

Immune ResponseUnknown status

GonorrheaPreclinical

Active, not recruiting

Vaccine ResponsePreclinical

Completed

Immune ResponsePreclinical

Unknown status

Competition

Competitive Landscape

24 competitors in Immune Response

#DrugCompanyPhaseTrials

Influenza Vaccine

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Xylocaine

MMEDRx USA, Inc.

Flumist

Decadron

AAspen Global Incorporated

INMAZEB

Rmenb+omv

Immunonutrition

SSt. Antonius Hospital

Ervebo

AANRS, Emerging Infectious Diseases

Rabies Vaccine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity2 trials

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

Completed· GSK logo

GSK·Phase 2·NCT03433482·1,707 enrolled

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Completed· GSK logo

GSK·Phase 3·NCT04707391·1,250 enrolled

Immune Response2 trials

Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

Unknown status·SSwiss Federal Institute of Technology·N/A·NCT06116669·180 enrolled

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Completed· GSK logo

GSK·Phase 1/2·NCT04886154·1,440 enrolled

Vaccine1 trial

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Completed· GSK logo

GSK·Phase 2·NCT03587207·520 enrolled

COVID-191 trial

Investigating a Vaccine Against COVID-19

Completed·UUniversity of Oxford·Phase 2/3·NCT04400838·10,811 enrolled

Gonorrhea1 trial

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Completed· Pfizer logo

Pfizer··NCT05873751·1,307,378 enrolled

1 more indication

Vaccine Response1 trial

Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

Completed·NNicole Stoffel·N/A·NCT05919472·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for MenACWY liquid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MenACWY liquid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MenACWY liquid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GSK

Related News